The "Drug Overview: QVM149" report has been added to ResearchAndMarkets.com's offering.
QVM149 (Novartis) is a fixed triple combination product consisting of a long-acting muscarinic antagonist (glycopyrronium bromide), a long-acting beta 2 agonist (LABA) (indacaterol), and an inhaled corticosteroid (ICS) (mometasone furoate). QVM149 is in Phase III development for the treatment of moderate to severe asthma uncontrolled with standard ICS/LABA therapies.
Key Topics Covered:
Product Profiles
QVM149: Asthma
List of Figures
Figure 1: Spiriva sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 2: Symbicort for asthma - SWOT analysis
List of Tables
Table 1: QVM149 drug profile
Table 2: QVM149 Phase III trials in asthma
Table 3: QVM149 sales for asthma across Japan and the five major EU markets, by country M, 2017-26
For more information about this report visit https://www.researchandmarkets.com/research/kj52wl/qvm149_novartis?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20180514006238/en/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.